Aim: Analyze changes on body composition in obese and T2DM patients treated with semaglutide.

Methods: Observational, prospective study. Body composition was studied by bioimpedance (BIO) . Changes were evaluated over a median of 26 wk. Paired Wilcoxon test was used to analyze the differences.

Results: 54 patients (53.7% women, mean age 53.5+/-21yr) . Table 1 shows data at baseline and follow up. We found a reduction in body weigh (-3.5 kg (2.7-4.3) p=0.00) mainly related to fat mass (-6 kg (4.1-8.5) p=0.00) with a little loss of lean (-2.6 (1.3-4.1) p=0.0004) and muscle mass (-0.8 (0.0004-1.6) p=0.04) (Fig 1)

Discussion: Sarcopenic Obesity is highly prevalent in T2DM associated with comorbidities like HBP, CVD or HF. Semaglutide induces significant weight loss due to a decrease in fat mass with preservation of muscle mass.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at